Abstract:Exploring alternative biomedical use of traditional drugs in different disease models is highly important as it can reduce the cost of drug development and overcome several critical issues of traditional chemodrugs such as low chemotherapeutic efficiency, severe side effect, and drug resistance. Disulfiram (DSF), a clinically approved alcohol-aversion drug, was recently demonstrated to feature tumor-growth suppression effect along with the co-administration of Cu2+ species, but direct Cu2+ administration mode might cause severe toxicity originating from low Cu2+ accumulation into the tumor and nonspecific Cu2+ distribution-induced cytotoxicity. Based on the intriguing drug-delivery performance of nanoscale metal-organic frameworks (MOFs), we herein construct HKUST nMOFs as the Cu2+ self-supplying nanocarriers for efficient delivery of the DSF drug. The mildly acidic condition of tumor microenvironment initially triggered the release of Cu ions from HKUST nMOFs, which further reacted with the encapsulated DSF to form toxic Cu(DDTC)2 (activation) for tumor chemotherapy. Especially, during the Cu(DDTC)2 complexation, Cu+ species were formed concomitantly, triggering the intratumoral nanocatalytic therapy for the generation of reactive oxygen species to synergistically destroying the tumor cells/tissue. As a result, synergetic tumor-responsive chemotherapy and nanocatalytic therapy are enabled by DSF@HKUST nanodrugs, as demonstrated by the dominant anticancer efficacy with satisfied biocompatibility both in vitro and in vivo. The present work offers a sophisticated strategy for tumor-responsive nontoxic-to-toxic therapeutic with high biocompatibility.

Self-supplying Cu 2+ and H 2 O 2 synergistically enhancing disulfiram-mediated melanoma chemotherapy

Nanomedicine-based Disulfiram and Metal Ion Co-Delivery Strategies for Cancer Treatment

Disulfiram-loaded CuO2 nanocarriers for enhanced synergistic chemodynamic chemotherapy

Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment

Buffet-style Cu(II) for enhance disulfiram-based cancer therapy

Co-delivery of a tumor microenvironment-responsive disulfiram prodrug and CuO2 nanoparticles for efficient cancer treatment

V9302-loaded copper-polyphenol hydrogel for enhancing the anti-tumor effect of disulfiram

Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate

Disulfiram: A novel repurposed drug for cancer therapy

Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems

Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens

Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways

A Cascade Nanoplatform for the Regulation of the Tumor Microenvironment and Combined Cancer Therapy.

Two birds with one stone: Copper metal-organic framework as a carrier of disulfiram prodrug for cancer therapy

N-Oxide Polymer-Cupric Ion Nanogels Potentiate Disulfiram for Cancer Therapy.

Anticancer Drug Disulfiram for In Situ RAFT Polymerization: Controlled Polymerization, Multifacet Self-Assembly, and Efficient Drug Delivery

In situ triggering antitumor efficacy of alcohol-abuse drug disulfiram through Cu-based metal-organic framework nanoparticles

Tumor-responsive copper-activated disulfiram for synergetic nanocatalytic tumor therapy

The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics

Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways

A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer